Last reviewed · How we verify
NCT05732779
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
NA trial testing DOT intervention in Heart Transplant Rejection in 100 participants. Currently enrolling.
1 February 2027
Quick facts
| Lead sponsor | University of Florida |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 October 2024 |
| Primary completion | 1 February 2027 |
| Estimated completion | 1 May 2027 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- DOT intervention
Conditions studied
- Heart Transplant Rejection — all drugs for Heart Transplant Rejection →
- Immune Suppression — all drugs for Immune Suppression →
- Pediatric Heart Transplant — all drugs for Pediatric Heart Transplant →
- Medication Nonadherence — all drugs for Medication Nonadherence →
Sponsor
University of Florida
Who can join
Adults 10 to 21, any sex, with Heart Transplant Rejection or Immune Suppression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05732779
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Transplant Rejection
Currently open trials in the same condition.
- NCT07531784 — A National Swedish Study Evaluating Dd-cfDNA for as a Diagnostic Biomarker for Rejection Surveillence in Heart Transplan · recruiting
- NCT06656065 — IMR-Heart Trasplant Study · recruiting
- NCT05205551 — Prospera Test Evaluation in Cardiac Transplant (ProTECT) · active not recruiting
- NCT05184426 — MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT) · active not recruiting
Other University of Florida trials
Trials by the same sponsor.
- NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
- NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
- NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
- NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
- NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05732779 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Florida
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05732779.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing